ArticleHeliyon2024
The navel nanoethosomal formulation of gamma-oryzanol attenuates testicular ischemia/reperfusion damages.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Ameliorative effect of selenium nanoparticles combined with post-conditioning on testicular ischemia-reperfusion injury in rats.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testicular torsion reduces blood flow to testes and induces tissue ischemia. Antioxidant can have pivotal roles in alleviation of the effects of torsion/reperfusion. Gamma-oryzanol (γ-Oryzanol) has several pharmacological properties such as antioxidant and anti-apoptosis that can be used in this way. This study was conducted to evaluate the effects of nanoethosomal formulation of gamma-oryzanol (γ-Oryzanol-NEs) on testicular damages in a mouse model of ischemia/reperfusion damage. Following induction of ischemia/reperfusion, the mice were treated with γ-Oryzanol and γ-Oryzanol-NEs (6 mg/kg) in times of 3 h and 6 h. The expression of positive cells of TUNEL, superoxide dismutase (SOD), glutathione peroxidase (GPx), heat shock protein-70 (HSP70) and caspase 3 and histopathological parameters were assessed. The results showed higher expression of positive cells of TUNEL, HSP70 and caspase 3 and lower expressions of SOD and GPx in control mice compared with those treated with γ-Oryzanol-NEs (P = 0.001). The treatment with γ-Oryzanol-NEs could decrease pathological damages and the expression of positive cells of TUNEL, HSP70 and caspase 3 and increase the expressions of SOD and GPx. In conclusion, γ-Oryzanol-NEs could have the protective effects on torsion/reperfusion by decreasing apoptosis and increasing antioxidant status in a mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.